Sten Scheibye was born on 3 October 1951 and is a Danish national. He has a MSc in Chemistry and Physics from 1978 and a PhD in Organic Chemistry from 1981, both from the University of Aarhus, Denmark, and a BComm from the Copenhagen Business School, Denmark, from 1983.
From 1995 to 2008 Sten Scheibye was president and CEO of Coloplast A/S, Denmark. Before joining Coloplast in 1993, Mr Scheibye served as senior vice president, sales & marketing in Leo Pharma A/S, Denmark. He joined Leo Pharma in 1981.
Mr Scheibye is chairman of the Board of Directors of the Novo Nordisk Foundation, the Danish Industry Foundation, the Rich. Müller Foundation, RMIG A/S and the Knud Højgaards Foundation.
Göran A. Ando was born on 6 March 1949 and is a Swedish national. Dr Ando is a specialist in General Medicine and a Founding Fellow of the American College of Rheumatology in the US. Dr Ando is former Executive Vice President and President of Research & Development of Pharmacia Corporation, which was acquired by Pfizer Inc. in 2003.
In April 2003, he was appointed CEO of the Celltech Group PLC in the UK until its acquisition in 2004 by UCB.
Dr Ando is Chairman of the Board of Directors of Novo Nordisk A/S and Symphogen A/S and a member of the Board of Directors of Molecular Partners and EUSA Pharma and ICMEC.
Dr Ando serves as a Senior Advisor to Essex Woodlands Health Ventures UK Ltd.
Jeppe Christiansen was born on 25 November 1959 and is a Danish national. He holds an MSc in Economics from the University of Copenhagen. Since 2004, Jeppe Christiansen has been CEO of Maj Invest A/S, of which he is also a co-founder.
From 1986 to 1988, Jeppe Christiansen worked as an economist in Sparekassen SDS. He came to LD Pensions in 1988 where he became Head of Fund Management and later, as Executive Vice President, responsible for investments. From 1998 to 2004, Jeppe Christiansen worked as a Director in Danske Bank, responsible for international equity investments and corporate clients.
Jeppe Christiansen is Vice Chairman of the Board of Directors of Novo Nordisk A/S and a member of the Boards of Haldor Topsøe A/S, Kirkbi A/S and Symphogen A/S.
Steen Riisgaard was born on 22 March 1951 and is a Danish national. He holds a MSc in Microbiology from the University of Copenhagen.
Steen Riisgaard was President and CEO of Novozymes A/S from the demerger from Novo Nordisk A/S in 2000 and until April 2013. He joined Novo Nordisk in 1979 in Enzymes Research & Development, and in 1982 he moved to Tokyo to start up an enzymes research & development unit in the Novo Nordisk subsidiary Novo Industri Japan Ltd. After his return to Denmark in 1985, he held a range of jobs in the company before he was promoted to Corporate Executive Vice President with special responsibility for Enzyme Business in 1989.
Prior to joining Novo Nordisk, he was a research fellow at the Serum Institute of Denmark and a research microbiologist at Foss Electric, Denmark.
Mr Riisgaard is Chairman of the Board of Directors of ALK-Abello A/S, Cowi A/S, Egmont International Holding A/S and Xellia Pharmaceuticals A/S. Furthermore, he is Chairman of WWF (the World Wildlife Fund) Denmark, Vice Chairman of the Boards of the Novo Nordisk Foundation and the Villum Foundation, and serves on the Board of Aarhus University, Corbion and VKR Holding.
Per Wold-Olsen was born on 6 November 1947 and is a Norwegian national. He holds an MBA in Economics Administration as well as an MBA in Management and Marketing.
Per Wold-Olsen joined Merck & Co. (MSD) in 1974. He became Managing Director of the Norwegian subsidiary in 1976 and Regional Director and Vice President of the Scandinavian region in 1986. In 1991, Per Wold-Olsen was appointed Senior Vice President for Worldwide Human Health Marketing of Merck & Co. Inc. in the US, and in 1994, he was appointed President of Human Health Europe of Merck & Co., Inc. In 1997, his region increased to include Eastern Europe, the Middle East and Africa, and Worldwide Human Health Marketing. In 2005, he was appointed President of the Human Health Intercontinental Region, Merck & Co. Inc. From 1994 to 2006 he was also a member of Merck’s Management Committee.
Per Wold-Olsen is Chairman of the Board of Directors of GN Store Nord A/S and of Medicines for Malaria Venture, and serves on the Board of Directors of Exiqon A/S and Gilead Sciences Inc.